Accelerated Infliximab Induction for Severe Lower Gastrointestinal Bleeding in a Young Patient with Crohn's Disease: A Case Report

被引:1
|
作者
Zeng, Jing [1 ]
Shen, Feng [1 ]
Fan, Jian-Gao [1 ]
Ge, Wen-Song [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol, Xinhua Hosp, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
Crohn's disease; Severe lower gastrointestinal bleeding; Steroid hormone; Accelerated infliximab induction; Case report; HEMORRHAGE;
D O I
10.12998/wjcc.v10.i2.733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Severe lower gastrointestinal bleeding (SLGIB) is a rare complication of Crohn's disease (CD). The treatment of these patients is a clinical challenge. Monoclonal anti-TNF alpha antibody (IFX) can induce relatively fast mucosal healing. It has been reported for the treatment of SLGIB, but there are few reports on accelerated IFX induction in CD patients with SLGIB. CASE SUMMARY A 16-year-old boy with a history of recurrent oral ulcers for nearly 1 year presented to the Gastroenterology Department of our hospital complaining of recurrent periumbilical pain for more than 1 mo and having bloody stool 4 times within 2 wk. Colonoscopy showed multiple areas of inflammation of the colon and a sigmoid colon ulcer with active bleeding. Hemostasis was immediately performed under endoscopy. The physical examination of the patient showed scattered small ulcers in the lower lip of the mouth and small cracks in the perianal area. Combined with his medical history, physical examination, laboratory examinations with high C-reactive protein (CRP), platelet count (PLT), erythrocyte sedimentation rate (ESR) and fecal calprotectin levels, imaging examinations and pathology, a diagnosis of CD was taken into consideration. According to the pediatric CD activity index 47.5, methylprednisolone (40 mg QD) was given intravenously. The abdominal pain disappeared, and CRP, PLT, and ESR levels decreased significantly after the treatment. Unfortunately, he had a large amount of bloody stool again after 1 wk of methylprednisolone treatment, and his hemoglobin level decreased quickly. Although infliximab (IFX) (5 mg/kg) was given as a combination therapy regimen, he still had bloody stool with his hemoglobin level decreasing from 112 g/L to 80 g/L in a short time, so-called SLGIB. With informed consent, accelerated IFX (5 mg/kg) induction was given 7 days after initial presentation. The bleeding then stopped. Eight weeks after the treatment, repeat colonoscopy showed mucosal healing; thus far, no recurrent bleeding has occurred, and the patient is symptom-free. CONCLUSION This case highlights the importance of accelerated IFX induction in SLGIB secondary to CD, especially after steroid hormone treatment.
引用
收藏
页码:733 / 740
页数:8
相关论文
共 50 条
  • [41] Autoimmune hepatitis during infliximab therapy for Crohn's disease: A case report
    Doyle, Adam
    Forbes, Geoff
    Kontorinis, Nick
    JOURNAL OF CROHNS & COLITIS, 2011, 5 (03) : 253 - 255
  • [42] Severe Refractory Orofacial Crohn’s Disease: Report of a Case
    Sandra Quezada
    Patricia L. Turner
    Borislav Alexiev
    Barry Daly
    Raymond Cross
    Digestive Diseases and Sciences, 2009, 54 : 2290 - 2295
  • [43] Severe Refractory Orofacial Crohn's Disease: Report of a Case
    Quezada, Sandra
    Turner, Patricia L.
    Alexiev, Borislav
    Daly, Barry
    Cross, Raymond
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (10) : 2290 - 2295
  • [44] Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature
    Sanam Verma
    Karen I Kroeker
    Richard N Fedorak
    BMC Gastroenterology, 13
  • [45] Prevalence and Risk Factors of Acute Lower Gastrointestinal Bleeding in Crohn Disease
    Li, Guanwei
    Ren, Jianan
    Wang, Gefei
    Wu, Qin
    Gu, Guosheng
    Ren, Huajian
    Liu, Song
    Hong, Zhiwu
    Li, Ranran
    Li, Yuan
    Guo, Kun
    Wu, Xiuwen
    Li, Jieshou
    MEDICINE, 2015, 94 (19)
  • [46] Lower gastrointestinal bleeding in Crohn's disease: How (un-)common is it and how to tackle it?
    Daperno, Marco
    Sostegni, Raffaello
    Rocca, Rodolfo
    DIGESTIVE AND LIVER DISEASE, 2012, 44 (09) : 721 - 722
  • [47] Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature
    Verma, Sanam
    Kroeker, Karen I.
    Fedorak, Richard N.
    BMC GASTROENTEROLOGY, 2013, 13
  • [48] Effect of Infliximab Induction Therapy on Secondary Systemic Amyloidosis Associated with Crohn's Disease: Case Report and Review of the Literature
    Pukitis, Aldis
    Zake, Tatjana
    Groma, Valerija
    Ostrovskis, Evalds
    Skuja, Sandra
    Pokrotnieks, Juris
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2013, 22 (03) : 333 - 336
  • [49] Appendix intussusception in a young patient with Crohn's disease
    Faul, A.
    Laforest, A.
    Fuks, D.
    JOURNAL OF VISCERAL SURGERY, 2020, 157 (04) : 355 - 357
  • [50] Ineffectiveness of infliximab therapy in severe infantile Crohn's disease
    Uslu, Nuray
    Usta, Yusuf
    Saltik-Temizel, Inci Nur
    Demir, Hulya
    Gurakan, Figen
    Ozen, Hasan
    Yuce, Aysel
    JOURNAL OF CROHNS & COLITIS, 2010, 4 (01) : 106 - 109